Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

November 1, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Nasopharyngeal Carcinoma
Interventions
DRUG

Toripalimab

PD-1 inhibitor

RADIATION

IMRT to the nasopharynx and neck

IMRT to the nasopharynx and neck

DRUG

Gemcitabine and Cisplatin Chemotherapy

Systemic chemotherapy

DRUG

Adjuvant chemotherapy with Capecitabine

Adjuvant chemotherapy after radiation

Trial Locations (1)

200032

Xiaomin Ou, Shanghai

All Listed Sponsors
collaborator

Fudan University Eye and ENT Hospital

UNKNOWN

collaborator

Anhui Provincial Hospital

OTHER_GOV

collaborator

Sir Run Run Shaw Hospital

OTHER

collaborator

Hangzhou Cancer Hospital

OTHER

collaborator

Ningbo Medical Center Lihuili Hospital

OTHER_GOV

collaborator

The First People's Hospital of Changzhou

OTHER

collaborator

Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center

OTHER

collaborator

Affiliated Cancer Hospital & Institute of Guangzhou Medical University

OTHER

collaborator

Nanfang Hospital, Southern Medical University

OTHER

collaborator

Shenzhen People's Hospital

OTHER

collaborator

First Affiliated Hospital of Xi'anJiaotong Univerisity

UNKNOWN

collaborator

Guangzhou Panyu Central Hospital

OTHER

collaborator

Fujian Cancer Hospital

OTHER_GOV

lead

Fudan University

OTHER